Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

Xehetasun bibliografikoak
Egile Nagusiak:	Sasson, SC, Zaunders, J, Nahar, K, Munier, C, Read, SA, Ahlensteil, G, Palendira, U, Scolyer, RA, Carlino, M, Long, GV, Menzies, AM, Kelleher, AD
Formatua:	Conference item
Hizkuntza:	English
Argitaratua:	Elsevier 2019

Antzeko izenburuak

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis
nork: Sasson, SC, et al.
Argitaratua: (2020)

Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
nork: Sasson, SC, et al.
Argitaratua: (2019)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
nork: Serigne Lo, et al.
Argitaratua: (2020-10-01)

Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
nork: David Anson, et al.
Argitaratua: (2019-01-01)

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
nork: Ian M. Bouligny, et al.
Argitaratua: (2025-02-01)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
nork: Adnan Kilani, et al.
Argitaratua: (2023-01-01)

Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
nork: A. Ciernik, et al.
Argitaratua: (2024-01-01)

The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma
nork: Foteini Kalofonou, et al.
Argitaratua: (2024-10-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
nork: Alexander D. Woods, MD, et al.
Argitaratua: (2025-03-01)

A case of ruptured Baker's cyst induced by nivolumab and ipilimumab
nork: Marie Kubo, et al.
Argitaratua: (2023-06-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
nork: Valerie Glutsch, et al.
Argitaratua: (2024-12-01)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
nork: Tetsuya Danno, et al.
Argitaratua: (2021-01-01)

Large‐cell neuroendocrine carcinoma of the kidney effectively treated by nivolumab and ipilimumab
nork: Nodoka Okubo, et al.
Argitaratua: (2025-03-01)

Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma
nork: Narayanan Sadagopan, et al.
Argitaratua: (2019-01-01)

Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab
nork: Yana Beulque, et al.
Argitaratua: (2024-08-01)

Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
nork: Drew M Pardoll, et al.
Argitaratua: (2020-10-01)

Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
nork: Vidhya Karivedu, et al.
Argitaratua: (2019-01-01)

Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
nork: Santosh Kesari, et al.
Argitaratua: (2024-12-01)

Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
nork: Razelle Kurzrock, et al.
Argitaratua: (2022-12-01)

Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
nork: Arun Singh, et al.
Argitaratua: (2020-05-01)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
nork: Vidhya Karivedu, et al.
Argitaratua: (2019-01-01)

Case report: Ipilimumab and nivolumab in metastatic adrenocortical cancer with high tumor mutational burden
nork: Rebekka Mispelbaum, et al.
Argitaratua: (2024-06-01)

First-line Nivolumab plus Ipilimumab in patients with advanced melanoma previously treated with adjuvant systemic therapy
nork: K. Kisielewska, et al.
Argitaratua: (2024-01-01)

Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab
nork: David Liu, et al.
Argitaratua: (2024-08-01)

Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumab
nork: Jiajia Chen, et al.
Argitaratua: (2025-12-01)

Correction: Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective study
Argitaratua: (2020-10-01)

Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
nork: Taylor C. Peak, et al.
Argitaratua: (2020-01-01)

Efficacy and safety of nivolumab plus ipilimumab in gastrointestinal cancers: a systematic review and meta-analysis
nork: Bowen Dai, et al.
Argitaratua: (2025-01-01)

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
nork: Masatoshi Kudo
Argitaratua: (2024-08-01)

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature
nork: Craig L. Slingluff, et al.
Argitaratua: (2016-12-01)

Checkpoint inhibitor immunotherapy induced inflammatory arthritis secondary to Nivolumab and Ipilimumab: a pediatric first
nork: John A. Storwick, et al.
Argitaratua: (2024-04-01)

Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage
nork: Bushra Khan, et al.
Argitaratua: (2024-05-01)

Evaluating the efficacy and safety of nivolumab and ipilimumab combination therapy compared to nivolumab monotherapy in advanced cancers (excluding melanoma): a systemic review and meta-analysis
nork: Hussain Sohail Rangwala, et al.
Argitaratua: (2024-05-01)

21067. LEPTOMENINGITIS TRAS TRATAMIENTO CON NIVOLUMAB E IPILIMUMAB. A PROPÓSITO DE UN CASO
nork: N. Txurruka Mugartegi, et al.
Argitaratua: (2024-11-01)

Lambert-Eaton Myasthenic Syndrome Secondary to Nivolumab and Ipilimumab in a Patient with Small-Cell Lung Cancer
nork: Kavita Agrawal, et al.
Argitaratua: (2019-01-01)

Nivolumab and ipilimumab therapy in a patient with non-small cell lung cancer with chronic kidney disease
nork: Hiroaki Satoh, et al.
Argitaratua: (2022-06-01)

Lichen striatus as an immune-related adverse event following ipilimumab/nivolumab and COVID-19 infection in an adult
nork: Courtney M. Kenyon, BS, et al.
Argitaratua: (2024-10-01)

Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma
nork: Shimpei Yamashita, et al.
Argitaratua: (2024-05-01)

Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy
nork: Khalid Jazieh, et al.
Argitaratua: (2024-05-01)

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
nork: Alexandra Leary, et al.
Argitaratua: (2024-08-01)